Schonfeld Strategic Advisors LLC Decreases Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)

Schonfeld Strategic Advisors LLC cut its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 26.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 109,500 shares of the company's stock after selling 39,855 shares during the period. Schonfeld Strategic Advisors LLC owned about 0.21% of Janux Therapeutics worth $5,863,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. FMR LLC lifted its stake in shares of Janux Therapeutics by 10.8% in the 4th quarter. FMR LLC now owns 8,669,941 shares of the company's stock valued at $464,189,000 after purchasing an additional 845,266 shares during the period. Adage Capital Partners GP L.L.C. raised its stake in shares of Janux Therapeutics by 47.6% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,061,750 shares of the company's stock valued at $163,926,000 after purchasing an additional 986,750 shares during the period. Vanguard Group Inc. boosted its stake in Janux Therapeutics by 15.6% during the fourth quarter. Vanguard Group Inc. now owns 2,136,332 shares of the company's stock valued at $114,379,000 after buying an additional 288,402 shares during the period. Lord Abbett & CO. LLC increased its stake in Janux Therapeutics by 80.2% in the 4th quarter. Lord Abbett & CO. LLC now owns 1,267,803 shares of the company's stock worth $67,878,000 after acquiring an additional 564,322 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of Janux Therapeutics by 596.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,109,978 shares of the company's stock valued at $59,429,000 after acquiring an additional 950,557 shares in the last quarter. Institutional investors own 75.39% of the company's stock.

Insider Buying and Selling

In related news, Director Ra Capital Management, L.P. bought 341,742 shares of the business's stock in a transaction on Wednesday, March 5th. The shares were bought at an average price of $30.64 per share, for a total transaction of $10,470,974.88. Following the completion of the purchase, the director now directly owns 9,658,988 shares of the company's stock, valued at approximately $295,951,392.32. This trade represents a 3.67 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Andrew Hollman Meyer sold 3,334 shares of Janux Therapeutics stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $32.15, for a total transaction of $107,188.10. Following the completion of the transaction, the insider now directly owns 82,139 shares in the company, valued at approximately $2,640,768.85. The trade was a 3.90 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 10,001 shares of company stock valued at $313,964 over the last quarter. 29.40% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

JANX has been the subject of several research analyst reports. Wedbush reiterated an "outperform" rating and set a $76.00 target price (up from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. Scotiabank decreased their price objective on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a report on Friday, February 28th. HC Wainwright reaffirmed a "buy" rating and set a $70.00 target price on shares of Janux Therapeutics in a report on Monday, March 3rd. Finally, William Blair restated an "outperform" rating on shares of Janux Therapeutics in a report on Friday, January 10th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $95.25.

Janux Therapeutics Price Performance

Shares of NASDAQ:JANX traded down $0.22 during midday trading on Wednesday, hitting $25.32. The company had a trading volume of 415,047 shares, compared to its average volume of 978,167. The company has a fifty day moving average of $29.61 and a two-hundred day moving average of $42.21. The company has a market cap of $1.50 billion, a price-to-earnings ratio of -21.64 and a beta of 3.24. Janux Therapeutics, Inc. has a 12-month low of $22.52 and a 12-month high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, beating analysts' consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. Research analysts expect that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.